Posted by Michael Wonder on 22 Mar 2021
Triple therapy recommended by NICE for patients with multiple myeloma
22 March 2021 - The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.
Carfilzomib with dexamethasone and lenalidomide could be offered to around 2,000 patients with multiple myeloma who have had at least one previous therapy, which include bortezomib.
